Novel membrane-targeted antibiotics against drug-resistant Gram-positive bacterial infections [ 2016 - ]

Research Grant

Researchers: Dr Mark Blaskovich (Principal investigator) ,  Prof Matthew Cooper (Principal investigator) ,  Dr Karl Hansford ,  Prof David Paterson ,  Prof Jason Roberts

Brief description This project aims to develop a best in class antibiotic, Vancapticin, with superior efficacy, broader spectra of action and improved therapeutic index than existing therapies for Gram-positive (G+ve) bacterial infections. The research team has identified lead candidates that offer equivalent &/or superior potency, efficacy & pharmacokinetic profiles compared to several clinical comparators. NHMRC Development funding is required to select a candidate for an Investigative New Drug application.

Funding Amount $1,351,496.00

Funding Scheme Development Grants

Notes Development Grant